Dietary Mentha piperita essential oil loaded in chitosan nanoparticles mediated the growth performance and humoral immune responses in Siberian sturgeon (Acipenserbaerii).

Siberian sturgeon (Acipenser baerii) fry often face environmental stressors that can compromise their immune system, rendering them susceptible to opportunistic pathogens in intensive aquaculture systems. In this study, we explored the innovative use of chitosan nanoparticles loaded with Mentha piperita essential oil (MPO/CNPs) as a dietary supplement to improve the growth and immune responses of A. baerii. The results demonstrated that the addition of MPO/CNPs to the diet led to significant improvements in growth, as evidenced by increased red blood cell count, hematocrit, haemoglobin concentration, and reduced triglyceride levels. Furthermore, significant differences were observed in the immune parameters for the treatment groups receiving Mentha piperita essential oil loaded in chitosan nanoparticles (MPO/CNPs), including enhanced lysozyme activity, immunoglobulin M (IgM) levels, respiratory burst activity, and ACH50 activity. Additionally, gene expression analysis revealed upregulation of key immune-related genes in the MPO/CNPs-treated groups. These findings suggest that the use of MPO/CNPs can enhance the growth and bolster the immune defences of Siberian sturgeon fry, contributing to more sustainable production in intensive aquaculture environments.

Dietary supplementation of Salvinia cucullata in white shrimp Litopenaeus vannamei to enhance the growth, nonspecific immune responses, and disease resistance to Vibrio parahaemolyticus.

The current study investigates the effect of ethanolic extract of Salvinia cucullata (EESC) on growth, non-specific immune parameters, and disease resistance to Vibrio parahaemolyticus in Litopenaeus vannamei. The in-vitro cytotoxicity investigation was performed on shrimp hemolymph hemocytes to assess the toxicity and immunological responses with various concentrations of EESC, and no significant difference in cell viability was seen across dosages, but substantial changes in Phenol Oxidase (PO) and phagocytosis were reported. The in-vivo investigation was conducted on white shrimp for 56 days using varied amounts of 0 (control), 5 (EESC5), 10 (EESC10), and 20 (EESC20) g kg-1 containing feeds and challenged against Vibrio parahaemolyticus. The shrimp fed the EESC10 diet gained the most weight, had the highest specific growth rate (SGR) and had a better feed conversion ratio (FCR). The highest cumulative survival percentage was noted on the EESC10 diet-fed shrimps followed by EESC20 and EESC5 groups after the bacterial challenge with V. parahaemolyticus. The results of immune parameters such as total protein, total carbohydrate, coagulation time, total hemocytes count (THC), superoxide dismutase (SOD), ProPO, and phagocytosis levels were better in the EESC10 group. EESC5 and EESC20 groups were also shown better immunomodulatory effects than the control group. In conclusion, the oral administration of EESC was found to be an effective functional feed additive to improve the growth, immune parameters, and disease resistance against V. parahaemolyticus in L.vannamei.

Oral pre-administration of Purslane polysaccharides enhance immune responses to inactivated foot-and-mouth disease vaccine in mice.

BACKGROUND: Foot-and-mouth disease (FMD) is one of the greatest disease threats to animal husbandry worldwide. Though various vaccines against foot-and-mouth disease virus (FMDV) have been developed, vaccine effectiveness is still not satisfactory. In this work, we studied the potential ability of Purslane polysaccharide (POL-P3b) as a nutrient food additive to enhance immune responses to FMD vaccination in mice. RESULTS: Our results demonstrated that oral administration of POL-P3b at mid- and high-doses significantly enhanced the FMDV-specific cellular and humoral immune responses in mice and increased the concentration of Ca2+ in lymphocytes. Importantly, POL-P3b could promote intestinal DC maturation and stimulate the secretion of intestinal SIgA in a dose-dependent manner. Moreover, the acute toxicity study showed that POL-P3b was non-toxic and safe in mice. CONCLUSION: Our findings provided solid evidence that POL-P3b might be a novel immunostimulator and a boosting agent for increasing the efficacy of FMD vaccination, and the mechanism was related to stimulating the intestinal mucosal immune function that subsequently enhanced the efficacy of FMD vaccination through pre-administration of oral POL-P3b.

Understanding yeast shells: structure, properties and applications.

Background and purpose: The employment of yeasts for biomedical purposes has become increasingly frequent for the delivery of prophylactic and therapeutic products. Its structural components, such as ß-glucans, mannan, and chitin, can be explored as immunostimulators that show safety and low toxicity. Besides, this system minimizes antigen degradation after administration, facilitating the delivery to the target cells. Review approach: This review sought to present molecules derived from yeast, called yeast shells (YS), and their applications as carrier vehicles for drugs, proteins, and nucleic acids for immunotherapy purposes. Furthermore, due to the diversity of information regarding the production and immunostimulation of these compounds, a survey of the protocols and immune response profiles generated was presented. Key results: The use of YS has allowed the development of strategies that combine efficiency and effectiveness in antigen delivery. The capsular structure can be recognized and phagocytized by dendritic cells and macrophages. In addition, the combination with different molecules, such as nanoparticles or even additional adjuvants, improves the cargo loading, enhancing the system. Activation by specific immune pathways can also be achieved by different administration routes. Conclusion: Yeast derivatives combined in different ways can increase immunostimulation, enhancing the delivery of medicines and vaccine antigens. These aspects, combined with the simplicity of the production steps, make these strategies more accessible to be applied in the prevention and treatment of various diseases.

Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice.

Rabies is a preventable zoonotic disease caused by rabies virus (RABV) with high mortality. Messenger RNA (mRNA) vaccines have opened up new avenues for vaccine development and pandemic preparedness with potent scalability, which may overcome the only licensed rabies inactived vaccine' shortcoming of time and cost wasting. Here, we designed an RABV mRNA vaccines expressed RABV G protein and capsulated with lipid nanoparticle (LNP) and different nucleic acid immunostimulator (CPG 1018, CPG 2395 and Poly I:C) and then assessed the immunogenicity and protective capacity in mice. While RABV mRNA capsulated with LNP and CPG 1018 could induce more potent humoral response with highest and durable RABV-G specific IgG titers and virus neutralizing titers, but also induced stronger RABV G-specific cell-mediated immunity (CMI) responses, including the highest proportions of interferon-γ (IFN-γ) and tumor necrosis factor alpha (TNFα)- producing CD4+/CD8 + T cells according to a flow cytometry assay in mice. In addition, in the pre- and post-exposure challenge assays, LNP + CPG 1018 capsulated RABV G mRNA induced 100 % protection against 25 LD50 of RABV infection with highest inhibition efficacy of viral replication with the decreased virus genome detected by qRT-PCR. These results showed that RABV G mRNA capsulated with LNP immune-stimulating nucleic acids CPG 1018 showed promise as a safe and economical rabies vaccine candidate.

Polysaccharide from Atractylodes macrocephala Koidz binding with zinc oxide nanoparticles: Characterization, immunological effect and mechanism.

Atractylodes macrocephala Koidz (A. macrocephala) has been used both as a traditional medicine and functional food for hundreds of years in Asia. And it has a variety of biological activities, such as enhancing the ability of immunity and modulating effect on gastrointestinal motility. In this study, a water-soluble polysaccharide with molecular weight of 2.743 × 103 Da was isolated from the root of A. macrocephala. Polysaccharide from A. macrocephala (AMP) consisted of arabinose, galactose, glucose, xylose, mannose, ribose, galactose uronic acid, glucose uronic acid, with a percentage ratio of 21.86, 12.28, 34.19, 0.43, 0.92, 0.85, 28.79, and 0.67%, respectively. Zinc plays an important role in immune system. Therefore, we supposed that AMP binding with zinc oxide (ZnO) nanoparticles (AMP-ZnONPs) might be an effective immunostimulator. AMP-ZnONPs was prepared by Borch reduction, and its structural features were characterized by Scanning Electron Microscope (SEM), Transmission electron microscope (TEM), TEM-energy dispersive spectroscopy mapping (TEM-EDS mapping), Fourier transform infrared spectroscopy (FT-IR), X-ray photoelectron spectrometer (XPS), X-ray diffraction (XRD), particle size and zeta-potential distribution analysis. Then, its immunostimulatory activity and the underlying mechanism were evaluated using RAW264.7 cells. The results showed that AMP-ZnONPs remarkably promoted cell proliferation, enhanced phagocytosis, the release of nitric oxide (NO), cytokines (IL-6 and IL-1ß) and the expression of co-stimulatory molecules (CD80, CD86 and MHCII). Moreover, AMP-ZnONPs could promote the expression of Toll-like receptor 4 (TLR4), Myeloid differentiation factor 88 (MyD88), TNF receptor associated factor 6 (TRAF6), phospho-IκBα (P-IκBα) and phospho-p65 (P-p65), and TLR4 inhibitor (TAK242) inhibited the expression of these proteins induced by AMP-ZnONPs. Therefore, AMP-ZnONPs activated macrophages by TLR4/MyD88/NF-κB signaling pathway, indicating that AMP-ZnONPs could act as a potential immunostimulator in medicine and functional food.

Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice.

Theoretically, the subunit herpes zoster vaccine ShingrixTM could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have made its application economically impracticable. With lipid nanoparticles (LNPs) that were approved by the FDA as vectors for severe acute respiratory syndrome coronavirus 2 vaccines, we designed a series of vaccines efficiently encapsulated with varicella-zoster virus glycoprotein E (VZV-gE) and nucleic acids including polyinosinic-polycytidylic acid (Poly I:C) and the natural phosphodiester CpG oligodeoxynucleotide (CpG ODN), which was approved by the FDA as an immunostimulator in a hepatitis B vaccine. Preclinical trial in mice showed that these LNP vaccines could induce VZV-gE IgG titers more than 16 times those induced by an alum adjuvant, and immunized serum could block in vitro infection completely at a dilution of 1:80, which indicated potential as a varicella vaccine. The magnitude of the cell-mediated immunity induced was generally more than 10 times that induced by the alum adjuvant, indicating potential as a zoster vaccine. These results showed that immunostimulatory nucleic acids together with LNPs have promise as safe and economical varicella and zoster vaccine candidates.

The immunostimulator Victrio activates chicken toll-like receptor 21.

The immunostimulator Victrio consists of bacterial plasmid DNA encased in cationic liposomes and protects embryonated chicken eggs and newly hatched chickens against Escherichia coli induced mortality. It is demonstrated that Victrio specifically and potently activates recombinant chicken toll-like receptor 21 (TLR21) in a nuclear factor kappa B reporter gene assay. This TLR21 stimulatory activity is dependent on the presence of nonmethylated CpG and requires liposomal formulation of the DNA, as naked plasmid DNA proves to be inactive. Nitric oxide production is induced by Victrio in HD11 chicken macrophages that express TLR21 naturally, supporting the proposal that chicken TLR21 is a component of the molecular mode of action of Victrio.

Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity.

BACKGROUND: Amphotericin B (AmB) as a liposomal formulation of AmBisome is the first line of treatment for the disease, visceral leishmaniasis, caused by the parasite Leishmania donovani. However, nephrotoxicity is very common due to poor water solubility and aggregation of AmB. This study aimed to develop a water-soluble covalent conjugate of gold nanoparticle (GNP) with AmB for improved antileishmanial efficacy and reduced cytotoxicity. METHODS: Citrate-reduced GNPs (~39 nm) were functionalized with lipoic acid (LA), and the product GNP-LA (GL ~46 nm) was covalently conjugated with AmB using carboxyl-to-amine coupling chemistry to produce GNP-LA-AmB (GL-AmB ~48 nm). The nanoparticles were characterized by dynamic light scattering, transmission electron microscopy (TEM), and spectroscopic (ultraviolet-visible and infrared) methods. Experiments on AmB uptake of macrophages, ergosterol depletion of drug-treated parasites, cytokine ELISA, fluorescence anisotropy, flow cytometry, and gene expression studies established efficacy of GL-AmB over standard AmB. RESULTS: Infrared spectroscopy confirmed the presence of a covalent amide bond in the conjugate. TEM images showed uniform size with smooth surfaces of GL-AmB nanoparticles. Efficiency of AmB conjugation was ~78%. Incubation in serum for 72 h showed <7% AmB release, indicating high stability of conjugate GL-AmB. GL-AmB with AmB equivalents showed ~5-fold enhanced antileishmanial activity compared with AmB against parasite-infected macrophages ex vivo. Macrophages treated with GL-AmB showed increased immunostimulatory Th1 (IL-12 and interferon-γ) response compared with standard AmB. In parallel, AmB uptake was ~5.5 and ~3.7-fold higher for GL-AmB-treated (P<0.001) macrophages within 1 and 2 h of treatment, respectively. The ergosterol content in GL-AmB-treated parasites was ~2-fold reduced compared with AmB-treated parasites. Moreover, GL-AmB was significantly less cytotoxic and hemolytic than AmB (P<0.01). CONCLUSION: GNP-based delivery of AmB can be a better, cheaper, and safer alternative than available AmB formulations.

Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants.

Adjuvants have been of great interest to vaccine formulation as immune-stimulators. Prior to the recent research in the field of immune stimulation, conventional adjuvants utilized for aluminum-based vaccinations dominated the adjuvant market. However, these conventional adjuvants have demonstrated obvious defects, including poor protective efficiency and potential side effects, which hindered their widespread circulation. Outer membrane vesicles (OMVs) naturally exist in gram-negative bacteria and are capable of engaging innate and adaptive immunity and possess intrinsic adjuvant capacity. They have shown tremendous potential for adjuvant application and have recently been successfully applied in various vaccine platforms. Adjuvants could be highly effective with the introduction of OMVs, providing complete immunity and with the benefits of low toxicity; further, OMVs might also be designed as an advanced mucosal delivery vehicle for use as a vaccine carrier. In this review, we discuss adjuvant development, and provide an overview of novel OMV adjuvants and delivery vehicles. We also suggest future directions for adjuvant research. Overall, we believe that OMV adjuvants would find high value in vaccine formulation in the future.

Synthesis of a hemin-containing copolymer as a novel immunostimulator that induces IFN-gamma production.

BACKGROUND: Hemozoin, a chemical analog of a malarial pigment, is a crystal composed of heme dimers that can act as a potent Th1-type adjuvant, which strongly induces antibody production. However, the clinical applications of malarial hemozoin have limitations due to biosafety concerns and difficulties in the manufacturing process. Based on the premise that an analog of the heme polymer might display immunostimulatory effects, a hemin-containing polymer was developed as a novel immunostimulator. MATERIALS AND METHODS: To synthesize the copolymer containing hemin and N-isopropylacrylamide (NIPAM), this study employed a conventional radical polymerization method using 2,2'-azodiisobutyronitrile as the radical initiator; the synthesized copolymer was designated as NIPAM-hemin. RESULTS: NIPAM-hemin was soluble and showed no cytotoxicity in vitro. The NIPAM-hemin copolymer induced the production of interferon (IFN)-γ and interleukin (IL)-6 from peripheral blood mononuclear cells, although hemin and the NIPAM monomer individually did not induce the production of any cytokines. The production of IFN-γ induced by NIPAM-hemin was independent of toll-like receptor 9 and the NLRP3 inflammasome pathway. CONCLUSION: Given that NIPAM-hemin induced IL-6 and IFN-γ production in immune cells without any cytotoxic effects, NIPAM-hemin has potential therapeutic applications as a Th1-type adjuvant.

Application of arteether-loaded polyurethane nanomicelles to induce immune response in breast cancer model.

To concentrate a potent anticancer drug (Arteether) in tumor microenvironment, we encapsulated it in biodegradable and pH sensitive polyurethane (PU) nanomicelles (NMs). The nanocomplex was characterized by Fourier transform infrared (FTIR), dynamic light scattering (DLS). The loading capacity and release profile in pH of 5.4 and 7.4 were considered. The cytotoxicity effect was evaluated in vitro and in vivo settings. The level of IFN-γ and IL-4 cytokines of mice splenocytes were assessed by enzyme-linked immunosorbent assay (ELISA). The nanocomplex showed negative zeta charge of -26.2 mV, size of 42.30 nm and high loading capacity (92%). Release profile showed a faster rate of drug liberation at pH 5.4 as compared to that of pH 7.4. It indicated significant inhibitory effect on the growth of 4T1 cell line and increased IFN-γ level.

Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators.

The development of subunit vaccines has become very attractive in recent years due to their superior safety profiles as compared to traditional vaccines based on live attenuated or whole inactivated pathogens, and there is an unmet medical need for improved vaccines and vaccines against pathogens for which no effective vaccines exist. The subunit vaccine technology exploits pathogen subunits as antigens, e.g., recombinant proteins or synthetic peptides, allowing for highly specific immune responses against the pathogens. However, such antigens are usually not sufficiently immunogenic to induce protective immunity, and they are often combined with adjuvants to ensure robust immune responses. Adjuvants are capable of enhancing and/or modulating immune responses by exposing antigens to antigen-presenting cells (APCs) concomitantly with conferring immune activation signals. Few adjuvant systems have been licensed for use in human vaccines, and they mainly stimulate humoral immunity. Thus, there is an unmet demand for the development of safe and efficient adjuvant systems that can also stimulate cell-mediated immunity (CMI). Adjuvants constitute a heterogeneous group of compounds, which can broadly be classified into delivery systems or immunostimulators. Liposomes are versatile delivery systems for antigens, and they can carefully be customized towards desired immune profiles by combining them with immunostimulators and optimizing their composition, physicochemical properties and antigen-loading mode. Immunostimulators represent highly diverse classes of molecules, e.g., lipids, nucleic acids, proteins and peptides, and they are ligands for pattern-recognition receptors (PRRs), which are differentially expressed on APC subsets. Different formulation strategies might thus be required for incorporation of immunostimulators and antigens, respectively, into liposomes, and the choice of immunostimulator should ideally be based on knowledge regarding the specific PRR expression profile of the target APCs. Here, we review state-of-the-art formulation approaches employed for the inclusion of immunostimulators and subunit antigens into liposome dispersion and their optimization towards robust vaccine formulations.

Dietary ß-glucan enhances the contents of complement component 3 and factor B in eggs of zebrafish.

ß-glucan has been shown to increase non-specific immunity and resistance against infections or pathogenic bacteria in several fish species, but no information is available regarding its trans-generational effects to date. Here we clearly demonstrated that ß-glucan enhanced the contents of immune-relevant molecules C3 and Bf in eggs of zebrafish, and the embryos derived from ß-1,3 glucan-treated zebrafish were more resistant to bacterial challenge than control embryos. Moreover, the transferred C3 and Bf were directly associated with the antimicrobial defense of early embryos. In addition, feeding female zebrafish with ß-glucan had little detrimental effects on the number of spawned eggs and their embryonic development. Collectively, these data show for the first time that ß-glucan can be safely used to promote the non-specific immunity in offspring of fishes.

Peperomia pellucida leaf extract as immunostimulator in controlling motile aeromonad septicemia due to Aeromonas hydrophila in red hybrid tilapia, Oreochromis spp. farming.

AIM: This study was revealed the potential of Peperomia pellucida leaf extract as an immunostimulator agent in controlling motile aeromonad septicemia due to Aeromonas hydrophila in red hybrid tilapia, Oreochromis sp. MATERIALS AND METHODS: In the present study, minimum inhibitory concentration (MIC) of P. pellucida leaf extract against A. hydrophila was determined through two-fold microbroth dilution method. The plant extract was screening for its active compound using a gas chromatograph mass spectrometer, and the effectiveness of P. pellucida leaf extract as an immunostimulator agent was evaluated. The experimental fish were fed with medicated feed at three different concentrations (25 mg/kg, PP-25; 50 mg/kg, PP-50; and 100 mg/kg, PP-100) of P. pellucida leaf extract for 1 week before they were intraperitoneally exposed to A. hydrophila. Enzyme-linked immunosorbent assay was carried out to determine the value of antibody response to A. hydrophila in fish from a group of fish that received medicated feed, and the percentage of total cumulative mortality of the experimental fish were observed at the end of the experiment. RESULTS: The results showed that the major bioactive compound is phytol (40%), and the MIC value was 31.5 mg/L. The value of antibody response to A. hydrophila in fish from a group of fish which received medicated feed (PP-25, 0.128±0.014 optical density [OD]; PP-50, 0.132±0.003 OD; and PP-100, 0.171±0.02 OD) was found significantly higher (p<0.05) compared to fish did not receive medicated feed (0.00 OD). Whereas, percentage cumulative mortality of fish from all groups of fish received medicated feed (PP-25, 18.0±3.2%; PP-50, 18.2±2.8%; and PP-100, 17.7±1.8%) were found significantly lower (p<0.05) compared to a group of fish did not receive medicated feed (83.2±1.4%). CONCLUSION: The findings of the present study indicated the huge potential of P. pellucida leaf extract as natural immunostimulator agent for aquaculture uses.

Influence of the immunomodulatory drug stimforte on the humoral immune response in the experimental herpes virus infection.

In the study of the immunostimulation preparation Stimforte activity using the model of the experimental herpes virus infection BALB/c, mice has shown that sera from mice treated with the drug on the 4th and 7th day after infection possessed a 3 times greater capability of specifically binding to the culture of HSV-1 (on cells Vero) according to dot blot analysis, as compared with intact infected mice sera obtained at the same time. It was also shown that these sera had a 5 times higher index of neutralization. On the basis of Western blots, it was detected that antibodies from sera of mice treated with Stimforte contacted the glycoproteins gB and gC of HSV-1 significantly better. Thus, Stimforte stimulates one of the strongest modulatory effects on the immune memory and is a promising drug for the treatment of chronic viral diseases.

The immunostimulatory effect of novel immunostimulator CH2b with a thiazolidin-4-one ring on the functions of LPS-activated RAW 264.7 macrophages in vitro.

This study was designed to confirm the effect of the novel immunostimulators CH1b and CH2b with a thiazolidin-4-one ring on the function of macrophages. We used these two molecules to stimulate LPS-activated RAW 264.7 macrophages in vitro. After a series of essential assays, we found that CH1b and CH2b could significantly increase the production of nitric oxide (NO) by the LPS-activated RAW 264.7 macrophages, and also found that CH2b could more significantly increase the proliferation, phagocytic activity, and secretion of IL-6, IL-8 and TNF-α by LPS-activated RAW 264.7 cells more than CH1b. Furthermore, CH2b could increase the degradation of IκB-α and could promote the nuclear translocation of nuclear factor (NF)-κB p65 in LPS-activated RAW 264.7 cells. However, CH2b could also increase the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK). Taken together, we got that CH2b could further increase the LPS-induced activation of NF-κB and p38 MAPK in RAW 264.7 macrophages to elevate the function of macrophages, including iNOS expression, NO production, cytokines secretion, and phagocytosis.

Effect of Immunos on immune response cells by azathioprine Induced immunosuppression in mice / Монголын Анагаах Ухаан

Background@#Herbal medicines continue to be widely used as natural promoters of good health, as immune-modulators in recent years. This situation is directly related to the rapid growth of natural based products, the decrease of chemical synthesized products and as well as the increase of natural substance consumption. @*Objective@#The purpose of this survey was to study influence of Immunos herbal medicines on immune system in the experimental and preclinical circumstances.@*Materials and Methods@#The immune deficiency was to created by Azathioprine through 5 days in the white mice after that control group, preparation of Immunal, Salimon and Immunos 1, 2 were administrated appropriate doses by oral during 10 days. Then we collected blood and quantified number of white blood cells (K/µL), quantity of splenocyte (×106 cell/ml), amount of CD4+, CD8+ and IgM, IgA, Ig G (mg/ml) (Elisa Kit Assay: Catalog. No: WAM-568 (Elisa Reader, 450 nm)-WKEA MED SUPPLIES CORP) on the 5th, 10th days.@*Results@#All statistical analyses were conducted with SPSS version 20.0 software (IBM, Armonk, NY). One-way ANOVA was used to assess statistical significance between Immunos groups and days of observation. Mean values of white blood cells in blood, quantity of splenocyte, CD4+, CD8+ and IgM, IgG levels determined in the control and experimental groups. White blood cells level were significantly increased in the Immunos group compared with the control group by 55.6 percent (11.5±0.9 K/µL vs 5.1±0.51 K/µL, p<0.001) and number of splenocyte increased Immunos group compared with the control group by 60.6 % (352.2±23.5 ×106 cell/ml vs 138.6±23.5 ×106 cell/ml, p<0.01). Therefore, CD4+, CD8+ and IgM, IgG levels were significantly increased in the Immunos group compared with the control group by 0.71 to 8.8% (IgG: 11.47±0.42 vs 10.45±0.43 μg/ml, IgM: 11.33±0.81 vs 10.48±0.31 μg/ml, CD4+: 10.44±0635 vs 10.04±0.372 U/ml, CD8+: 9.75±1.02 vs 9.68±0.45 U/ml p<0.02).@*Conclusion@#It’s concluded that, Immunos preparation shows immune-stimulator effect in cellular immunity and humoral immunity in the case of immunosuppressant by Azathioprine.

Effects of immunostimulator CH2 b on mixed peptides derived from glucose-6-phosphate isomerase induces arthritis / 中国免疫学杂志

Objective:To explore the effect of the synthetic immunomodulator CH 2b with a thiazolidin-4-one ring on the pathogenesis of rheumatoid arthritis (RA) mice induced by glucose-6-phosphate isomerase(GPI) mixed peptides.Methods:hGPI325-339 ,hGPI469-483 peptide fragments were mixed with complete freund′s adjuvant fully ,DBA/1 mice were givien subcutaneous injection of the emulsifiers,pertussis toxin to strengthen immunity.And then RA mice were intervened with α-GalCer and CH2b,the changes of body weight ,ankle joint symptoms scores were observed .The joint tissues stained with hematoxylin and eosin ( HE) was used to evaluate the inflammatory cells.Fluorescence-activated cell sorting ( FACS) was used to detect the frequency changes of iNKT cells .Cytometric bead array(CBA) was used to analyze the levels of serum cytokines TNF-α,IL-6,IL-4,IFN-γ.Results: Compared with the model group,α-GalCer,CH2b could reduce the inflammation of the model mice ,significantly improve the body weight growth and the joint swelling(P0.05).Conclusion:Immunomodulator CH2b by activating iNKT cells affect the secretion of inflammatory cytokines ,and it relieved the GPI induced arthritis .

The Application of Uro-vaxom(R), Urinary Tract Immunostimulator in the Treatment of Chronic Pelvic Pain Syndrome / 대한비뇨기과학회지

Purpose: There are a variety of techniques for treating chronic prostatitis. Regardless of the presence of infections, antibiotics were arbitrarily prescribed for 4-12 weeks, but there seemed to be ongoing debate of their effectiveness and side effects. Uro-vaxom(R) is known as an effective treatment for urinary tract infection due to its initiation the urothelial immune system activity. This study was performed to investigate for the possibility of Uro-vaxom(R) as a drug for use in non-inflammatory chronic prostatitis. Materials and Methods: 95 patients, diagnosed as chronic pelvic pain syndrome (CPPS) (National Institutes of Health (NIH)-category IIIB), were divided into three groups: group A, 35 patients were given levofloxacin 100mg TID and Uro-vaxom(R) 60mg OD for the first 4 weeks, followed by only Uro-vaxom(R) 60mg OD for the next 8 weeks; group B, 30 patients were given only Uro-vaxom(R) 60mg OD before breakfast for 12 weeks; group C, the patients were treated with levofloxacin 100mg TID for 4 weeks. All the patients were reevaluated 4 weeks and 12 weeks later. Results: The initial diagnostic stati, the NIH-Chronic Prostatitis Symptom Index (CPSI) were 25.1+/-2.7, 24.4+/-3.2 and 24.7+/-2.2 for groups A, B and C, respectively. In groups A and B, the NIH-CPSI after 12 weeks were 13.5 2.3 and 13.9+/-2.7, respectively, and showed noticeable improvements (p0.05). No patients experienced any adverse symptoms due to Uro-vaxom(R) intake. Conclusions: Uro-vaxom(R) could be appointed as an alternative method for the treatment of chronic prostatitis.